|NeoStem to launch $16.5m public offering|
|By Deborah Sterescu - Proactiveinvestors.com|
|Tuesday, 19 July 2011 17:55|
The company will issue 13.75 million units at $1.20 per unit. Each unit will consist of one common share and a warrant to purchas three quarters of a share at a per share price of $1.45.
NeoStem expects to receive $16.5 million in gross proceeds, prior to deducting underwriting discounts and commissions, as well as offering expenses.
The new funds will be used for working capital purposes, including research and development of cell therapeutic product candidates, expansion of business units and other general corporate purposes, it said.
Lazard Capital Markets and JMP Securities acted as joint bookrunners for the offering, while Morgan Joseph TriArtisan, Maxim Group and National Securities Corporation acted as co-managers.
The financing is expected to close around July 22, subject to customary closing conditions.
Since starting out as a stem-cell storage company, NeoStem has branched out into cell therapeutics, engaged in the development and manufacturing of cell-based therapies.
Its January 2011 acquisition of Progenitor Cell Therapy and its recent announcement of its plans to acquire Amorcyte position the company for further growth.
Proactiveinvestors is a leading news organisation and event business with offices in New York, Sydney, Toronto and London. The Company is a publisher and is not registered with the US Securities Exchange Commission or Ontario Securities Commission. Please read our full terms and conditions here http://www.proactiveinvestors.com/pages/terms